Telefon:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@antikoerper-online.de

Rekombinanter CTLA4 Antikörper

Dieses Maus Monoklonal-Antikörper erkennt spezifisch CTLA4 in IF und BR. Er zeigt eine Reaktivität gegenüber Maus.
Produktnummer ABIN7072468

Kurzübersicht für Rekombinanter CTLA4 Antikörper (ABIN7072468)

Target

Alle CTLA4 Antikörper anzeigen
CTLA4 (Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA4))

Antikörpertyp

Recombinant Antibody

Reaktivität

  • 153
  • 83
  • 45
  • 14
  • 3
Maus

Wirt

  • 90
  • 80
  • 22
  • 7
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
Maus

Klonalität

  • 129
  • 72
  • 3
Monoklonal

Konjugat

  • 108
  • 18
  • 13
  • 11
  • 9
  • 5
  • 4
  • 2
  • 2
  • 2
  • 2
  • 2
  • 2
  • 2
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
Dieser CTLA4 Antikörper ist unkonjugiert

Applikation

  • 97
  • 91
  • 63
  • 59
  • 45
  • 36
  • 18
  • 13
  • 10
  • 7
  • 6
  • 6
  • 4
  • 4
  • 3
  • 3
  • 2
  • 2
  • 2
  • 2
  • 2
  • 1
  • 1
  • 1
Immunofluorescence (IF), Blocking Reagent (BR)

Klon

9D9
  • Verwendungszweck

    Anti-CTLA-4 [9D9], Mouse IgG2b, kappa

    Spezifität

    The antibody is specific for CTLA-4.

    Produktmerkmale

    Original Species of Ab: Mouse

    Original Format of Ab: IgG2b

    Aufreinigung

    Protein A affinity purified

    Immunogen

    The antibody was raised against CTLA-4.

    Isotyp

    IgG2b kappa
  • Applikationshinweise

    The antibody has been used to block CTLA-4 and has been shown to enhance T-cell immunity against tumours (Quezada et al, 2006). 9D9 also has an anti-B16/BL6 melanoma effect in non-irradiated tumour-bearing recipients when given as combinatorial therapy with Gvax (Peggs et al, 2009). Selby et al. (PMID: 24777248) show how conversion of the original mouse IgG2b to a mouse IgG2a greatly increases anti-tumor activity of the 9D9 antibody in both MC38 (C57BL/6 mice) and CT26 (BALB/c mice) models. This mechanism both involves blockade of CTLA4 as well as depletion of tumor-infiltrating regulatory T-cells. Fc Silent antibodies were shown to have reduced anti-tumor activity as they did not deplete tumor infiltrating regulatory T-cells, however they lead to expansion of peripheral Tregs.

    Beschränkungen

    Nur für Forschungszwecke einsetzbar
  • Konzentration

    1 mg/mL

    Buffer

    PBS with 0.02 % Proclin 300.

    Konservierungsmittel

    ProClin

    Vorsichtsmaßnahmen

    This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

    Lagerung

    4 °C,-20 °C

    Informationen zur Lagerung

    Store at 4°C for up to 3 months. For longer storage, aliquot and store at -20°C.
  • Target

    CTLA4 (Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA4))

    Andere Bezeichnung

    CTLA-4

    Hintergrund

    CD152, CTLA4, Cytotoxic T-Lymphocyte Associated Protein 4, Insulin-Dependent Diabetes Mellitus 12, Celiac Disease 3, Ligand And Transmembrane Spliced Cytotoxic T Lymphocyte Associated Antigen 4, Cytotoxic T Lymphocyte Associated Antigen 4 Short Spliced Fo

    UniProt

    P09793

    Pathways

    Cancer Immune Checkpoints
Sie sind hier:
Chat with us!